Levi & Korsinsky Notifies Rocket Pharmaceuticals, Inc. (RCKT) Shareholders of Class Action Lawsuit and August 11, 2025 Deadline
https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=157694&wire=5&utm_campaign=15
or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.
Cannot view this video? Visit:
https://www.youtube.com/watch?v=bar7Q9XIFkc
THE LAWSUIT: A class action securities lawsuit was filed against Rocket Pharmaceuticals, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025.
CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Rocket's securities at artificially inflated prices.
On May 27, 2025, Rocket announced that the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event (SAE), ultimately, death, while enrolled in the study following a substantive amendment to the protocol that the Company failed to disclose to investors at the time management made the revision. In fact, Rocket stated that, while the patient was dosed in May, the decision to amend the protocol was made "several months" earlier. Despite this, Rocket made no attempt to alert investors or the public to the change until after the SAE occurred.
Following this news, the price of Rocket's common stock declined dramatically. From a closing market price of $6.27 per share on May 23, 2025, Rocket's stock price fell to $2.33 per share on May 27, 2025, a decline of about 37% in the span of just a single trading day.
WHAT'S NEXT? If you suffered a loss in Rocket stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=157694&wire=5&utm_campaign=15 to learn about your rights to seek a recovery. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259678
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
3 minutes ago
- National Post
FlavorSum Builds a Winning Formula for Growth with Warburg Pincus
Article content KALAMAZOO, Mich. — FlavorSum, a North American pure-play flavor solutions provider, today announced its acquisition by Warburg Pincus, a global private equity firm specializing in growth investments, from its prior owner, The Riverside Company. Article content The acquisition marks a significant milestone for FlavorSum and signals a new chapter in the company's growth and development. Under Riverside's ownership, FlavorSum expanded market reach, deepened its flavor portfolio, and assembled exceptional technical talent to accelerate innovation for high-growth, mid-sized, and emerging food and beverage brands. Article content 'We recognize the solid foundation and success we have built with the support of The Riverside Company,' said FlavorSum CEO Brian Briggs. 'During the past five years the FlavorSum team fully integrated four complementary acquisitions and added 35,000 square feet to our Michigan manufacturing facility. Our team is driving industry-leading growth with a solutions model that delivers operational excellence and an outstanding customer experience. We look forward to partnering with Warburg Pincus and expanding our pure-play flavor platform—both organically and as the 'Acquirer of Choice' for flavor companies committed to serving fast-growing, disruptive brands.' Article content 'FlavorSum's integrated business model strategically positions the company to meet the expanding interest in natural solutions across food and beverage categories,' said Zach Lazar, Managing Director at Warburg Pincus. 'The company's customer-driven approach unites responsive service with unparalleled flavor and application expertise. Through this partnership, we aim to advance FlavorSum's standout growth and acquisition strategy.' Article content The transaction will close later in the third quarter, pending customary regulatory approvals. FlavorSum engaged financial advisers Houlihan Lokey and law firm Jones Day to complete the agreement. Article content FlavorSum will continue to operate independently, with the existing leadership team shaping strategy and day-to-day operations. Article content About FlavorSum Article content FlavorSum Article content helps growing North American food and beverage companies go to market quickly and cost-effectively. The company provides flavor solutions for delivering great-tasting products that inspire loyalty among today's consumers. With nearly 100k square feet of manufacturing space across North America, along with a dedicated innovation center, FlavorSum is the fastest growing North American flavor company. Article content About Warburg Pincus Article content Warburg Pincus LLC Article content is the pioneer of private equity global growth investing. A private partnership since 1966, the firm has the flexibility and experience to focus on helping investors and management teams achieve enduring success across market cycles. Today, the firm has more than $87 billion in assets under management, and more than 220 companies in its active portfolio, diversified across stages, sectors, and geographies. Warburg Pincus has invested in more than 1,000 companies across its private equity, real estate, and capital solutions strategies. Article content The firm is headquartered in New York with offices in Amsterdam, Beijing, Berlin, Hong Kong, Houston, London, Luxembourg, Mumbai, Mauritius, San Francisco, São Paulo, Shanghai, and Singapore. Article content About The Riverside Company Article content is a global investment firm focused on being one of the leading private capital and credit options for business owners and portfolio company employees at the smaller end of the middle market by seeking to fuel transformative growth and create lasting value. Since its founding in 1988, Riverside has made more than 1,000 investments. The firm's current international private equity and flexible capital portfolios include more than 140 companies. Article content Article content Article content Article content Article content Contacts Article content
Globe and Mail
3 minutes ago
- Globe and Mail
Cover Whale Announces $40 Million in Growth Equity Financing from Morgan Stanley Expansion Capital to Fund Growth Initiatives
Cover Whale Insurance Solutions, Inc., a leading insurtech specializing in connected insurance for commercial auto, announced $40 million in new equity financing from Morgan Stanley Expansion Capital. The financing will enable Cover Whale to accelerate investments in its technology platform, analytics, and expand its product offerings to drive increased growth and profitability. Founded in 2020, Cover Whale's proprietary technology platform and algorithmic underwriting enables agents to bind trucking insurance policies online in minutes. By leveraging real-time telematics and other data sources, Cover Whale continuously underwrites policies throughout their term, achieving industry-leading loss ratios in the traditionally challenging commercial trucking market segment. Commenting on the financing, Dan Abrahamsen, Founder and CEO of Cover Whale, said: 'After years of rapid growth, 2024 marked a pivotal year for Cover Whale as we focused on re-building our foundation. We invested in our technology platform, built a high-performing service organization, and refined our pricing, underwriting and loss control programs. Morgan Stanley Expansion Capital's transition from lender to equity partner is a gratifying affirmation of the tremendous progress made over the past few years, and their renewed backing gives us the resources to fully capitalize on the significant growth opportunities ahead.' Year to date, Cover Whale has $133 million of gross written premiums during the first half of 2025, on track for a full-year target of $277 million. Morgan Stanley Expansion Capital first invested in Cover Whale in May 2024 with a structured debt instrument. 'Today's growth equity investment reflects our conviction in Cover Whale's business strategy, execution and leadership team,' said Nick Nocito, Executive Director of Morgan Stanley Expansion Capital. 'Over the last 18 months, the team has built a high-quality, scalable platform that we believe will generate significant growth in the coming years.' About Cover Whale Cover Whale is a leading insurtech on a mission to make commercial auto insurance faster, easier, and smarter—for agents, policyholders, and the broader insurance ecosystem. Grounded in technology, automation, and the strategic use of AI and real-time data, Cover Whale offers the industry's fastest quote and bind platform, while delivering industry leading loss ratios. The company's proprietary driver safety program combines continuous underwriting, real-time risk monitoring, telematics, and AI-powered driver coaching to reduce losses, reward safe driving, and improve road safety for both covered drivers and the motoring public. Operating as a managing general agent (MGA), Cover Whale has partnered with nearly 5,000 agents to write more than $1.3 billion in gross premium, since its inception in 2020. As it has grown, the organization has earned recognition across the industry, including being named a top insurtech to watch by PropertyCasualty360 and one of Forbes' Best Startup Employers. To learn more, visit and stay current via LinkedIn, Facebook, and their blog. About Morgan Stanley Expansion Capital Morgan Stanley Expansion Capital is the growth-focused private investment platform within Morgan Stanley Investment Management. MSEC targets late-stage growth equity and credit investments within technology, consumer, healthcare, and other high-growth sectors. For nearly four decades, Morgan Stanley Expansion Capital has successfully pursued growth investment opportunities and has completed investments in over 220 companies, leveraging the global brand and network of Morgan Stanley. About Morgan Stanley Investment Management Morgan Stanley Investment Management, together with its investment advisory affiliates, has over 1,400 investment professionals around the world and $1.7 trillion in assets under management or supervision as of June 30, 2025. Morgan Stanley Investment Management strives to provide outstanding long-term investment performance, client service, and a comprehensive suite of investment management solutions to a diverse client base, which includes governments, institutions, corporations, and individuals worldwide. For further information about Morgan Stanley Investment Management, please visit About Morgan Stanley
National Post
3 minutes ago
- National Post
Pluristyx Completes Investment Round to Expand Product Portfolio and Commercial Operations
Article content SEATTLE — Pluristyx, a leading provider of induced pluripotent stem cell (iPSC) technologies and proprietary gene editing solutions, today announced the successful close of its most recent round of funding led by BioLife Solutions, the global leader in cryopreservation technologies and systems that support cell and gene therapy (CGT) manufacturing, and BroadOak Capital Partners, a specialist investor in the life science tools and services industry. Article content The newly raised capital will enable Pluristyx to expand inventory with new clinical grade cell lines incorporating Pluristyx's proprietary FailSafe® and iACT™ engineering and hypoimmune genetic edits in its best-in-class, polyclonal, synthetic RNA reprogramed iPSCs. These proprietary cells are specifically designed to support making next-generation genetically engineered, stem cell-derived therapies and support uniquely safe, effective, and scalable living medicines. The funding will also support Pluristyx's recently launched PluriForm ™ kit, which provides researchers with streamlined tools for generating organoids and other complex test systems. Article content 'We are incredibly excited for the successful close of this round and gratified to have industry leaders and peers validate our vision with their investment,' said Benjamin Fryer, PhD, CEO of Pluristyx. 'The support from our Seattle area neighbor, BioLife Solutions, and continued support from our colleagues at BroadOak Partners will allow us to manufacture, commercialize, and distribute our innovative solutions and help our customers solve critical industry challenges.' Article content Roderick de Greef, BioLife's Chairman and CEO, remarked, 'We have known and worked with the founding team at Pluristyx for many years, and have a great deal of respect for their scientific expertise in cell therapy. Their recent development of an iPSC-based biological assay for organoid manufacturing dovetails with our interest in exploring biological assays more broadly as a product portfolio adjacency.' Article content 'We are excited to continue our support of Dr. Fryer and the entire Pluristyx team,' said Daniel Friedman, Principal at BroadOak Capital Partners. 'Pluristyx is differentiated by its suite of proprietary technologies that directly address some of the most critical scientific challenges of the iPSC field.' Article content iPSCs are unique tools and building blocks for medicines. In addition to applications for innovative new toxicology, safety, and efficacy assays to replace animal models, Pluristyx's products are the ideal universal raw material to produce living medicines to cure currently untreatable diseases. This strategic investment will enable Pluristyx to be the industry leader offering the highest quality stem cells available anywhere. Article content About BioLife Solutions Article content BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit or follow BioLife on LinkedIn and X. Article content About BroadOak Capital Partners Article content BroadOak Capital Partners is a boutique financial institution that provides direct investment and investment banking services to companies in the life science tools, diagnostics, and biopharma services sectors. BroadOak has led or participated in investments in over 70 companies across the life sciences industry. For more information, visit Article content Pluristyx is dedicated to enabling the development of next-generation cell-based tools and therapies. PluriKit™, PluriForm™ Organoids, and PluriBank™ stem cells incorporating safety and tolerance features like FailSafe®, iACT™, and hypoimmune engineering streamline developers' path to the clinic and approval. Pluristyx's iPSC lines, backed by an FDA registered drug master file, with platform genetic engineering are available 'off-the-shelf' along with comprehensive support services to accelerate the creation of novel diagnostics, screening and safety testing, and curative treatments. For more information, visit Article content Article content Article content Article content
